Physician profile
Nicholas E Lamparella
NPI 1073712741
$868.68
in general payments reported to CMS, 2019-2025
17 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2021: $11.92 · 2022: $100 · 2023: $162 · 2024: $175 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $498 · Food and Beverage: $62.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $497.73 |
| Food and Beverage | $62.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $282.93 | 2022-2025 | |
| Seagen INC. | $99.99 | 2025 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2024 | |
| Lilly USA, LLC | $91.01 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $62.21 | 2023 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $40.43 | 2019 | |
| Janssen Biotech, INC. | $40.35 | 2019 | |
| Daiichi Sankyo INC. | $22.50 | 2025 | Enhertu |
| Amgen INC. | $20.14 | 2019 | |
| Genentech USA, INC. | $19.32 | 2019 | |
| Astellas Pharma US INC | $19.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.86 | 2019 | |
| Pfizer INC. | $14.54 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Lamparella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.